NCT06435910
Engineered Dendritic Cell Vaccines for Multiple Myeloma
Not Yet Recruiting · Phase 1 · Shenzhen Geno-Immune Medical Institute · registry updated 2026-11-02
Inclusion and exclusion lines below are quoted from ClinicalTrials.gov. No match score is shown, because a score needs a person's age, biomarkers, and treatment dates. Confirm the record with the study team.
The purpose of this study is to determine the feasibility, safety, and efficacy of dendritic cell (DC) vaccines in the treatment of multiple myeloma (MM) or plasmacytoma based on immune-modified DC vaccines (DCvac). This approach is aimed to achieve prolonged maintenance of remission in multiple myeloma or plasmacytoma patients.
Inclusion
- Male and female subjects with multiple myeloma or plasmacytoma
- Very good partial or complete remission (CR) after prior combination therapies.
- Expected survival \> 12 weeks
- Adequate venous access for blood withdrawal or apheresis, and no other contraindications for blood withdrawal
- Voluntary informed consent is given with willingness to continue follow up
Exclusion
- Pregnant or lactating women
- Uncontrolled active infection
- HIV or active hepatitis B or hepatitis C infection
- Concurrent use of systemic steroids; the use of inhaled steroids is not exclusionary